Responses to PARP inhibition have been seen in patients with FANCA alterations [23,53] and preclinical data suggest that PTEN loss sensitises cancers to PARP inhibitors, with reported cases of exceptional responses to olaparib [54,55]. This evidence concerns the gene FANCA and cancer.